Search Clinical Trials
By Condition
By Location (USA)
By Location (Other)
By Sponsor
Resources
Privacy Policy
About Us
Disclaimer
A study of the safety and effects of EMD 72000 in subjects with recurrent ovarian cancer Clinical Trials Facts presented on Clinical Trials Search is not designed to be a substitute for certified medical advice, travels to or professional assistance by using a genuine doctor. We aren't mDs. Always consult your physician about A study of the safety and effects of EMD 72000 in subjects with recurrent ovarian cancer conditions. Clinical Trials Search.org is a website committed to listing clinical research studies in human subjects. A study of the safety and effects of EMD 72000 in subjects with recurrent ovarian cancer Clinical research trials and A study of the safety and effects of EMD 72000 in subjects with recurrent ovarian cancer health trials occur in a lot of of cities throughout the US. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally evaluate the potency of new does drugs. The role of the studies / undertakings is to figure out specific human healthcare questions. Clinical trials are a popular manner for mDs, government agencies, and private sector companies to locate treatments for all sorts of conditions, including A study of the safety and effects of EMD 72000 in subjects with recurrent ovarian cancer. A study of the safety and effects of EMD 72000 in subjects with recurrent ovarian cancer Clinical Trials and other clinical trials permit volunteers to get medical treatment choices before they are available to the general public. Many times the test subjects get professional assistance for free of charge, and occasionally they are compensated for their time. Sometimes there is a cost for a A study of the safety and effects of EMD 72000 in subjects with recurrent ovarian cancer clinical trial. Human subjects often get the best healthcare possible for their A study of the safety and effects of EMD 72000 in subjects with recurrent ovarian cancer condition. Risks are a reality, nevertheless, and could include additional or frequent dr. calls, medical hazards (perhaps life-threatening), and/or the treatment being ineffectual. Trials are federally governed with exacting guidelines to protect clinical trials patients.

Home > "A" Clinical Trials Conditions > A study of the safety and effects of EMD 72000 in subjects with recurrent ovarian cancer

A study of the safety and effects of EMD 72000 in subjects with recurrent ovarian cancer



A study of the safety and effects of EMD 72000 in subjects with recurrent ovarian cancer

For Condition: Ovarian Cancer
Status: Recruiting
Sponsor(s): EMD Pharmaceuticals , Merck KGaA
Synopsis: EMD 72000 is an experimental, biological drug. Studies in animals indicate that EMD 72000 blocks a factor found on the surface of many cancer cells. The factor is called epidermal growth factor receptor or EGFR. One type of cancer which frequently contains EGFR is ovarian cancer. This study will test the safety and effects of EMD 72000 in subjects with EGFR-positive recurrent ovarian cancer following standard treatment that has failed.
Details:
Eligibility:
Study Type:
  Interventional, Treatment, Open Label, Safety/Efficacy Study
Minimum Age/Maximum Age: 18 Years/
Genders: Female
Protocol Entry Criteria: Inclusion Criteria: - Recurrent ovarian cancer (including primary peritoneal cancer) following treatment (e.g., doxorubicin HCL liposome, topotecan, etc.) for primary or secondary platinum-refractory disease - Immunohistochemical evidence of tumor EGFR (HER-1) expression - At least one measurable lesion according to the WHO criteria - Life expectancy 12 weeks - ECOG performance status 0-1 Exclusion Criteria: - History of prior MAb therapy - History of prior treatment with an EGFR (HER-1) directed therapy - Known brain metastases - Presence of a Grade 2 pre-existing skin disorder (alopecia is permitted) - Known intercurrent infections or immunosuppression - Actively infected with, or chronic carriers of HBV - Evidence of HCV disease - Previous diagnosis of autoimmune disease - Known hypersensitivity to the administered drugs or any of their components - Receipt of chemotherapy, radiation therapy, or another investigational drug within 30 days of enrollment
Total Enrollment: 

Location and Contact Information:


Additional Information:
Study ID Numbers:
  EMD 72000-030; 
Study Start Date: 
Record last reviewed: November 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00073541

Other Ovarian Cancer Studies:
1. Breast Imaging Studies in Women at High Genetic Risk of Breast Cancer: Menstrual Cycle Study

2. A study of the safety and effects of EMD 72000 in subjects with recurrent ovarian cancer

3. SU5416 and Carboplatin to Treat Ovarian Cancer

4. Methods in Education for Breast Cancer Genetics

5. A Phase I Study of Infusional Paclitaxel with the P-Glycoprotein Antagonist PSC 833

Related Studies:

Other Ovarian Cancer Clinical Trials
Other Maryland Clinical Trials
Other Baltimore Clinical Trials

A study of the safety and effects of EMD 72000 in subjects with recurrent ovarian cancer

Modify your Search

  Other Ovarian Cancer Clinical Trials
  Other Maryland Clinical Trials
  Other Baltimore Clinical Trials


Warning: include(/var/www/cgi-bin/traxis/counter.php) [function.include]: failed to open stream: No such file or directory in /home/cts/domains/clinicaltrialssearch.org/public_html/index.php on line 103

Warning: include() [function.include]: Failed opening '/var/www/cgi-bin/traxis/counter.php' for inclusion (include_path='.:/usr/local/lib/php') in /home/cts/domains/clinicaltrialssearch.org/public_html/index.php on line 103